

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1801)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 24, 2026

Reference is made to the circular (the “**Circular**”) of Innovent Biologics, Inc. (the “**Company**”) incorporating, amongst others, the notice (the “**Notice**”) of annual general meeting of the Company (the “**AGM**”) dated June 1, 2026. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

All the Directors, namely Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors attended the AGM in person or by electronic means.

At the AGM held on June 24, 2026, all the proposed resolutions as set out in the Notice were duly passed by way of poll and the poll results were as follows:

ORDINARY RESOLUTIONS			Number of Votes (%)	
			For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of directors and the auditor of the Company for the year ended December 31, 2025		1,012,398,870 99.926399%	745,689 0.073601%
2.	(i)	To re-elect Mr. Ronald Hao Xi Ede as an executive director of the Company	1,002,463,253 99.266673%	7,405,644 0.733327%
	(ii)	To re-elect Ms. Joyce I-Yin Hsu as an independent non-executive director of the Company	947,069,527 93.723977%	63,418,456 6.276023%
	(iii)	To re-elect Dr. Stephen A. Sherwin as an independent non-executive director of the Company	1,009,156,725 99.865926%	1,354,834 0.134074%
3.	To authorise the board of directors of the Company (the “ Board ”) to fix the remuneration of the Directors		996,100,246 98.573860%	14,411,313 1.426140%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
4.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the Board to fix their remuneration	780,303,059 77.218618%	230,208,500 22.781382%
5.	To grant a general mandate to the directors to buy back shares of the Company (excluding any shares that are held as treasury shares, if any)	1,009,646,233 99.914368%	865,326 0.085632%
6.	To grant a general mandate to the directors to allot, issue and deal with additional shares of the Company (excluding any shares that are held as treasury shares, if any)	639,862,877 63.320689%	370,648,682 36.679311%
7.	To extend the general mandate granted to the directors to issue shares of the Company by adding thereto the total number of the shares to be bought back by the Company (excluding any shares that are held as treasury shares, if any)	520,648,200 51.523231%	489,863,359 48.476769%

As more than 50% of votes were cast in favor of the ordinary resolutions nos. 1 to 7 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
June 25, 2026

Notes:

- (a) As at the date of the AGM, the total number of shares of the Company in issue was 1,738,281,103 shares.
- (b) The total number of shares of the Company entitling the holders to attend and vote on the resolutions at the AGM was 1,738,281,103 shares.
- (c) As at the date of AGM, Mr. Ronald Hao Xi Ede and his associates control the voting rights in respect of an aggregate of 2,372,760 Shares or underlying Shares. Mr. Ede and his associates had abstained from voting on the above proposed resolutions numbered 2(i) at the AGM.
- (d) As at the date of AGM, Ms. Joyce I-Yin Hsu and her associates control the voting rights in respect of an aggregate of 23,576 Shares. Ms. Hsu and her associates had abstained from voting on the above proposed resolutions numbered 2(ii) at the AGM.
- (e) The trustees of the share schemes of the Company held in aggregate 3,287,913 shares, and was required to abstain from voting on all the resolutions proposed at the AGM. Accordingly, the total number of shares entitling the holder to attend and vote on the resolutions at the AGM was 1,734,993,190 shares. Saved as disclosed, no shareholders of the Company were required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM.
- (f) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules.
- (g) Saved as disclosed above, no parties have stated their intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions proposed at the AGM.
- (h) The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (i) The full text of the above resolutions are set out in the AGM Notice.

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.